Skip to main content
GOSS
NASDAQ Life Sciences

Gossamer Bio Finalizes Distressed Debt Exchange, Converting $181M in Notes

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
9
Price
$0.167
Mkt Cap
$81.98M
52W Low
$0.14
52W High
$3.87
52W Position info
19% above low
Off High info
96% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

GOSS sits 19% above its 52-week low of $0.14.

Summary

Gossamer Bio announced the final results of its distressed debt exchange, successfully converting $181.05 million of its 5.00% Convertible Senior Notes due 2027 into new debt and highly dilutive equity.


Key Events · Financing and Capital Events · GOSS

  • Final Tender Results Announced

    Gossamer Bio announced the final results of its exchange offer for its 5.00% Convertible Senior Notes due 2027, following previous updates on the distressed debt exchange.

  • Significant Debt Converted

    $181.05 million in aggregate principal amount of existing convertible notes were successfully exchanged, providing a crucial reduction in immediate debt burden.

  • Remaining Debt Outstanding

    $18.95 million of the original 5.00% Convertible Senior Notes due 2027 will remain outstanding after the exchange offer.

  • New Securities Issued

    The exchange involved issuing new 7.50% Convertible Senior Secured First Lien Notes due 2030 (up to $72.0M), up to 317,647,058 shares of common stock (or prefunded warrants), and purchase warrants, indicating substantial dilution.


Analysis · GOSS · Life Sciences

This filing confirms the successful completion of the distressed debt exchange, a critical step for Gossamer Bio which has been facing severe financial distress, a going concern warning, and a Nasdaq delisting notice. While the exchange involves significant dilution through the issuance of new equity and warrants, it substantially reduces the company's immediate debt burden by converting $181.05 million of existing convertible notes. This provides a crucial lifeline and extends the company's financial runway, albeit at a high cost to existing shareholders. The remaining $18.95 million in notes will stay outstanding.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GOSS was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $82M. The 52-week trading range was $0.14 to $3.87. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GOSS - Latest Insights

GOSS
Sep 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.19
Real-time Price: $9.88 info
Change: -$1.31 (-12%) info
Market Cap: $59.7M info
GOSS
Sep 23, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $11.00
Real-time Price: $9.88 info
Change: -$1.12 (-10%) info
Market Cap: $59.7M info
GOSS
Sep 16, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $10.93
Real-time Price: $9.88 info
Change: -$1.05 (-10%) info
Market Cap: $59.7M info
GOSS
Sep 11, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $9.88 info
Change: Reverse Stock Split info
Market Cap: $59.7M info
GOSS
Sep 11, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $9.88 info
Change: Reverse Stock Split info
Market Cap: $59.7M info